R N Ichord1, S L Benedict2, A K Chan3, F J Kirkham4, U Nowak-Göttl5. 1. Department Neurology & Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Department Neurology, Primary Children's Hospital, University of Utah, Salt Lake City, Utah, USA. 3. Division of Hematology and Oncology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. 4. Neurosciences Unit, University College London Institute of Child Health, London, UK University hospital Southampton NHS Foundation Trust, Southampton, UK. 5. Department of Pediatric Hematology/Oncology, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
Abstract
OBJECTIVES: We evaluated clinical features, treatment practices and early outcome in a multicentre cohort of children with cerebral sinovenous thrombosis (CSVT). METHODS: Children with CSVT from 10 countries were enrolled from January 2003 to July 2007 in the International Paediatric Stroke Study. We analysed clinical symptoms, underlying conditions, antithrombotic treatment and neurological outcome at hospital discharge in 170 children. RESULTS: Of 170 children enrolled, 60% were male; median age 7.2 years (IQR 2.9-12.4). Headache, altered consciousness, focal deficits and seizures were common presenting clinical features. Infarction affected 37% and intracranial haemorrhage 31%. Risk factors included chronic disease in 50%; acute systemic illness or head/neck disorders 41%; prothrombotic state 20% and other haematological abnormality 19%. Discharge neurological status was normal in 48%, abnormal in 43% and unknown in 5%. Antithrombotic therapy was common, most often low molecular weight heparin was common, with significant regional variation in treatment practices. Mortality was low (4%) and was associated with no anticoagulation but not underlying chronic disease, anatomic extent of thrombosis or intracranial haemorrhage. Abnormal neurological status at discharge or death was associated with decreased level of consciousness at presentation and the presence of an identified prothrombotic state. CONCLUSIONS: Our study extends the observations of previously published smaller studies in children with CSVT that this is a morbid disease with diverse underlying causes and risk factors. Divergent treatment practices among highly specialised centres as well as limited data on treatment efficacy and safety suggest that further study of this condition is warranted. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVES: We evaluated clinical features, treatment practices and early outcome in a multicentre cohort of children with cerebral sinovenous thrombosis (CSVT). METHODS:Children with CSVT from 10 countries were enrolled from January 2003 to July 2007 in the International Paediatric Stroke Study. We analysed clinical symptoms, underlying conditions, antithrombotic treatment and neurological outcome at hospital discharge in 170 children. RESULTS: Of 170 children enrolled, 60% were male; median age 7.2 years (IQR 2.9-12.4). Headache, altered consciousness, focal deficits and seizures were common presenting clinical features. Infarction affected 37% and intracranial haemorrhage 31%. Risk factors included chronic disease in 50%; acute systemic illness or head/neck disorders 41%; prothrombotic state 20% and other haematological abnormality 19%. Discharge neurological status was normal in 48%, abnormal in 43% and unknown in 5%. Antithrombotic therapy was common, most often low molecular weight heparin was common, with significant regional variation in treatment practices. Mortality was low (4%) and was associated with no anticoagulation but not underlying chronic disease, anatomic extent of thrombosis or intracranial haemorrhage. Abnormal neurological status at discharge or death was associated with decreased level of consciousness at presentation and the presence of an identified prothrombotic state. CONCLUSIONS: Our study extends the observations of previously published smaller studies in children with CSVT that this is a morbid disease with diverse underlying causes and risk factors. Divergent treatment practices among highly specialised centres as well as limited data on treatment efficacy and safety suggest that further study of this condition is warranted. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Philip Connor; Mayte Sánchez van Kammen; Anthonie W A Lensing; Elizabeth Chalmers; Krisztián Kállay; Kerry Hege; Paolo Simioni; Tina Biss; Fanny Bajolle; Damien Bonnet; Sebastian Grunt; Riten Kumar; Olga Lvova; Rukhmi Bhat; An Van Damme; Joseph Palumbo; Amparo Santamaria; Paola Saracco; Jeanette Payne; Susan Baird; Kamar Godder; Veerle Labarque; Christoph Male; Ida Martinelli; Michelle Morales Soto; Jayashree Motwani; Sanjay Shah; Helene L Hooimeijer; Martin H Prins; Dagmar Kubitza; William T Smith; Scott D Berkowitz; Akos F Pap; Madhurima Majumder; Paul Monagle; Jonathan M Coutinho Journal: Blood Adv Date: 2020-12-22
Authors: Dmitriy Petrov; Michael Y Uohara; Rebecca Ichord; Zarina Ali; Laura Jastrzab; Shih-Shan Lang; Lori Billinghurst Journal: Childs Nerv Syst Date: 2017-01-14 Impact factor: 1.475
Authors: Julia Devianne; Nicolas Legris; Isabelle Crassard; Celine Bellesme; Yannick Bejot; Celine Guidoux; Fernando Pico; David Germanaud; Michael Obadia; Diana Rodriguez; Philippe Tuppin; Manoelle Kossorotoff; Christian Denier Journal: Neurology Date: 2021-09-20 Impact factor: 9.910
Authors: Aleksandra Mineyko; Adam Kirton; Lori Billinghurst; Nana Nino Tatishvili; Max Wintermark; Gabrielle deVeber; Christine Fox Journal: Pediatr Neurol Date: 2019-10-18 Impact factor: 3.372
Authors: Ryan J Felling; Sahar M A Hassanein; Jennifer Armstrong; Luis Aversa; Lori Billinghurst; Neil A Goldenberg; Jo Ellen Lee; Emily C Maxwell; Michael J Noetzel; Warren Lo Journal: Neurol Clin Pract Date: 2020-06